Roth Capital Initiates Coverage on Castle Biosciences, Inc. (CSTL) with Buy
Rating Change Roth Capital analysts initiated coverage on Castle Biosciences, Inc. (NASDAQ:CSTL) with a Buy rating on June 25, 2026. Market Context Castle Biosciences, Inc.
Read more
